InspireMD Announces Combined Financings of $58 Million
InspireMD (NASDAQ: NSPR) has secured combined financings of $58 million through a private placement (PIPE) and warrant exercises. The PIPE financing, led by OrbiMed and Marshall Wace, raised $40.1 million by issuing 16,556,184 shares at $2.42 per share. An additional $17.9 million was generated through warrant exercises triggered by FDA approval of the company's CGuard Prime carotid stent system.
The funding will support the U.S. commercial launch of CGuard Prime, which recently received FDA premarket application approval (PMA). The company benefits from a favorable reimbursement environment, including a national coverage decision for carotid stenting. BofA Securities served as the exclusive placement agent for the PIPE transaction, which is expected to close by August 1, 2025.
InspireMD (NASDAQ: NSPR) ha ottenuto finanziamenti complessivi per 58 milioni di dollari attraverso un collocamento privato (PIPE) e l'esercizio di warrant. Il finanziamento PIPE, guidato da OrbiMed e Marshall Wace, ha raccolto 40,1 milioni di dollari emettendo 16.556.184 azioni a 2,42 dollari per azione. Ulteriori 17,9 milioni di dollari sono stati generati dall'esercizio di warrant attivato dall'approvazione FDA del sistema di stent carotideo CGuard Prime dell'azienda.
I fondi supporteranno il lancio commerciale negli Stati Uniti di CGuard Prime, che ha recentemente ricevuto l'approvazione FDA per la domanda di mercato pre-approvata (PMA). L'azienda beneficia di un ambiente favorevole per il rimborso, inclusa una decisione nazionale di copertura per lo stenting carotideo. BofA Securities ha agito come agente esclusivo per il collocamento PIPE, la cui chiusura è prevista entro il 1 agosto 2025.
InspireMD (NASDAQ: NSPR) ha asegurado financiamientos combinados por un total de 58 millones de dólares mediante una colocación privada (PIPE) y el ejercicio de warrants. La financiación PIPE, liderada por OrbiMed y Marshall Wace, recaudó 40,1 millones de dólares mediante la emisión de 16.556.184 acciones a 2,42 dólares por acción. Se generaron otros 17,9 millones de dólares a través del ejercicio de warrants activado por la aprobación de la FDA del sistema de stent carotídeo CGuard Prime de la compañía.
Los fondos apoyarán el lanzamiento comercial en Estados Unidos de CGuard Prime, que recientemente recibió la aprobación de la FDA para la solicitud de comercialización previa al mercado (PMA). La empresa se beneficia de un entorno favorable de reembolso, incluida una decisión nacional de cobertura para el stent carotídeo. BofA Securities actuó como agente exclusivo de colocación para la transacción PIPE, cuyo cierre se espera para el 1 de agosto de 2025.
InspireMD (NASDAQ: NSPR)는 사모 배정(PIPE)과 워런트 행사로 총 5800만 달러의 자금을 확보했습니다. OrbiMed와 Marshall Wace가 주도한 PIPE 자금 조달을 통해 16,556,184주를 주당 2.42달러에 발행하여 4010만 달러를 모금했습니다. 또한 FDA의 CGuard Prime 경동맥 스텐트 시스템 승인으로 촉발된 워런트 행사로 1790만 달러가 추가로 조성되었습니다.
이번 자금은 최근 FDA 시판 전 승인(PMA)을 받은 CGuard Prime의 미국 상업 출시를 지원할 예정입니다. 회사는 경동맥 스텐팅에 대한 국가적 보험 적용 결정 등 유리한 보험 환경의 혜택을 받고 있습니다. BofA Securities가 PIPE 거래의 독점 배정 대행사를 맡았으며, 거래는 2025년 8월 1일까지 마무리될 예정입니다.
InspireMD (NASDAQ : NSPR) a sécurisé un financement combiné de 58 millions de dollars via un placement privé (PIPE) et l'exercice de bons de souscription. Le financement PIPE, mené par OrbiMed et Marshall Wace, a permis de lever 40,1 millions de dollars en émettant 16 556 184 actions à 2,42 dollars par action. Un montant supplémentaire de 17,9 millions de dollars a été généré grâce à l'exercice de bons déclenché par l'approbation de la FDA du système de stent carotidien CGuard Prime de la société.
Ce financement soutiendra le lancement commercial aux États-Unis de CGuard Prime, qui a récemment reçu l'approbation de la FDA pour sa demande de mise sur le marché (PMA). La société bénéficie d'un environnement favorable au remboursement, incluant une décision nationale de couverture pour le stenting carotidien. BofA Securities a agi en tant qu'agent exclusif pour la transaction PIPE, dont la clôture est prévue pour le 1er août 2025.
InspireMD (NASDAQ: NSPR) hat durch eine Privatplatzierung (PIPE) und die Ausübung von Warrants insgesamt 58 Millionen US-Dollar an Finanzmitteln gesichert. Die PIPE-Finanzierung, angeführt von OrbiMed und Marshall Wace, brachte 40,1 Millionen US-Dollar durch die Ausgabe von 16.556.184 Aktien zu je 2,42 US-Dollar ein. Weitere 17,9 Millionen US-Dollar wurden durch die Ausübung von Warrants generiert, die durch die FDA-Zulassung des CGuard Prime Karotis-Stentsystems des Unternehmens ausgelöst wurden.
Die Finanzierung wird den kommerziellen US-Start von CGuard Prime unterstützen, das kürzlich die FDA-Zulassung für die vorläufige Markteinführung (PMA) erhalten hat. Das Unternehmen profitiert von einem günstigen Erstattungsumfeld, einschließlich einer nationalen Deckungsentscheidung für Karotis-Stents. BofA Securities fungierte als exklusiver Platzierungsagent für die PIPE-Transaktion, deren Abschluss bis zum 1. August 2025 erwartet wird.
- Secured substantial funding of $58 million to support commercial growth
- FDA approval received for CGuard Prime carotid stent system
- Strong backing from major investors OrbiMed and Marshall Wace
- Favorable reimbursement environment with national coverage decision
- Best-in-class clinical trial data from pivotal U.S. study
- Significant shareholder dilution through issuance of 16.5 million new shares
- Securities offered are restricted and not immediately tradeable
Insights
InspireMD secures $58M financing to commercialize its FDA-approved carotid stent, strengthening its position in the stroke prevention market.
InspireMD has secured
The funding significantly strengthens InspireMD's balance sheet at an opportune moment. The company now has sufficient capital to execute a comprehensive U.S. commercial launch, which is supported by three key advantages: 1) Their newly bolstered financial position, 2) A favorable reimbursement environment including a national coverage decision for carotid stenting, and 3) Strong clinical data from their pivotal U.S. study that led to the PMA approval.
The financing structure reveals strong institutional confidence in InspireMD's commercial potential. The PIPE transaction includes 16,556,184 shares at
This financing provides InspireMD with the resources needed to establish market leadership in carotid intervention, a critical area for stroke prevention. The company's ability to attract this level of investment from sophisticated healthcare funds like OrbiMed signals strong confidence in both their technology and commercial strategy as they transition from development to revenue generation.
Proceeds Bolster Balance Sheet to Commercialize Recently FDA Approved Best-In-Class Carotid Stent
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the Company has raised approximately
The PIPE, with aggregate gross proceeds of
“This transaction accomplished several key objectives to fund our growth plan as we launch CGuard Prime into the U.S. market,” said Marvin Slosman, CEO of InspireMD. “We fortified our shareholder base, broadened our investor reach and significantly strengthened our balance sheet giving us the ability to rapidly expand our commercial growth. With a strong balance sheet, favorable reimbursement environment including a national coverage decision (“NCD”) for carotid stenting and best in class clinical trial data generated from our pivotal U.S. study recently resulting in PMA approval, InspireMD is now poised to become the leader of the carotid intervention market.”
In connection with the PIPE, the Company entered into a registration rights agreement pursuant to which the Company will subsequently file a registration statement to register the resale of common stock purchased in the transaction and the common stock underlying the pre-funded warrants. The closing of the PIPE is expected to occur by August 1, 2025, subject to customary closing conditions.
InspireMD currently intends to use the net proceeds from the PIPE transaction to fund its operations, including, but not limited to, sales and marketing, research and development, and working capital and other general corporate purposes.
BofA Securities served as the exclusive placement agent for the PIPE with institutional investors. Greenberg Traurig acted as legal advisor to InspireMD. A&O Shearman acted as legal advisor to BofA Securities.
The securities issued in the private placement and unregistered pre-funded warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the unregistered shares, the pre-funded warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including expectations regarding the closing of the private placement, financial runway, U.S. commercial launch and expansion, and the exercise of any warrants. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
How much funding did InspireMD (NSPR) raise in July 2025?
What is the purpose of InspireMD's $58 million financing?
What was the share price for InspireMD's PIPE financing?
Who were the lead investors in InspireMD's PIPE financing?
When will InspireMD's PIPE financing close?
